PureTech Health (LON:PRTC)‘s stock had its “buy” rating reiterated by equities research analysts at Peel Hunt in a research report issued on Monday.
A number of other equities research analysts also recently weighed in on PRTC. Liberum Capital restated a “buy” rating on shares of PureTech Health in a research report on Tuesday, September 11th. Jefferies Financial Group boosted their target price on PureTech Health from GBX 245 ($3.20) to GBX 255 ($3.33) and gave the stock a “buy” rating in a research report on Tuesday, September 11th. Five investment analysts have rated the stock with a buy rating, PureTech Health has a consensus rating of “Buy” and a consensus target price of GBX 268.75 ($3.51).
PRTC stock opened at GBX 168 ($2.20) on Monday. PureTech Health has a twelve month low of GBX 111.50 ($1.46) and a twelve month high of GBX 183.50 ($2.40).
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.